MISSISSAUGA, Ontario, May 15, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the first quarter (Q1) ended March 31, 2025. Key highlights include: (CAD)Q1 2025% Change vs. Q1 2024Trailing Twelve Months (TTM) Mar 31, 2025% Change vs. TTM Mar 31, 2024Canadian Pharma Sales9,159,652+21%34,544,657+13%International Pharma Sales1,535,216<td colspan="2" style="border-right: solid black 1pt ; text-align: right ; ...

Core Viewpoint - Flexible Solutions International, Inc. reported a significant decline in sales and net income for the first quarter of 2025 compared to the same period in 2024, primarily due to lower sales volume and increased costs, while also highlighting recovery in order patterns and new market opportunities [2][3][5]. Financial Performance - Q1 2025 sales were $7,473,692, down approximately 19% from $9,224,872 in Q1 2024 [5][6]. - The net loss for Q1 2025 was ($277,734), or ($0.02) per share, compared to a net income of $457,226, or $0.04 per share in Q1 2024 [5][6]. - Non-GAAP operating cash flow for Q1 2025 was $480,268, or $0.04 per share, down from $1,382,874, or $0.11 per share in Q1 2024 [5][6]. Revenue Sources and Market Opportunities - The NanoChem division and ENP subsidiary remain the primary sources of revenue and cash flow for the company [3]. - New opportunities are emerging in various sectors including detergent, water treatment, oil field extraction, turf, ornamental, and agricultural use, as well as in food and nutrition supplement manufacturing [3][5]. Conference Call Information - A conference call is scheduled for May 16, 2025, at 11:00 AM Eastern Time, where CEO Dan O'Brien will present and answer questions regarding the financial results [4].

Core Insights - QuoteMedia, Inc. reported its highest quarterly revenue in company history for Q1 2025, amounting to $4,824,356, a 3% increase from $4,679,200 in Q1 2024 [3][7] - The company experienced a net loss of $499,811 in Q1 2025, compared to a net loss of $28,176 in Q1 2024, indicating a decrease in profitability [7][12] - Adjusted EBITDA for Q1 2025 was $368,269, down from $676,886 in Q1 2024, reflecting a reduction of $308,617 [7][12] Financial Performance - Quarterly revenue increased by $145,156 (3%) year-over-year, with a 5% growth on an FX-neutral basis [7][14] - The significant loss for the quarter was attributed to capitalizing a lower proportion of development costs compared to previous quarters, which increased expensed development costs [4][13] - The company expects continued growth throughout the year, aiming for its highest annual revenue ever [3][13] Business Overview - QuoteMedia provides a range of market data services, including streaming data feeds and financial applications, targeting banks, brokerage firms, and sophisticated investors [2][6] - The company competes with larger legacy organizations and smaller companies in the financial data sector [2] - QuoteMedia's offerings include interactive stock research tools and data feeds for major financial institutions [6]

Core Viewpoint - Stran & Company, Inc. reported strong financial results for Q1 2025, with significant revenue and gross profit growth, driven by both organic growth and the acquisition of Gander Group assets [2][3][4]. Financial Performance - Revenue increased by 52.4% year-over-year to approximately $28.7 million for Q1 2025, up from approximately $18.8 million in Q1 2024 [3]. - Gross profit rose by 51.1% to approximately $8.5 million, representing 29.6% of sales, compared to approximately $5.6 million or 29.8% of sales in the prior year [4][5]. - The Stran segment's sales increased to approximately $20.9 million, while the SLS segment, resulting from the Gander Group acquisition, generated approximately $7.8 million in sales [3]. Operational Highlights - The company achieved organic revenue growth of 11.2%, indicating resilience in a challenging market [2]. - The implementation of the NetSuite ERP system in January 2025 has improved automation, visibility, and process control, enhancing operational efficiency [2]. - Operating expenses increased by 43.6% to approximately $9.0 million, but as a percentage of sales, they decreased to 31.4% from 33.4% year-over-year [6]. Profitability and Loss - The net loss for Q1 2025 was approximately $0.4 million, a slight improvement from a net loss of approximately $0.5 million in Q1 2024, primarily due to increased gross profit [7]. Future Outlook - The company is focused on executing its strategy to enhance operational efficiency and expand margins while maintaining a strong balance sheet with approximately $12.2 million in cash and equivalents [2].

Year-over-year product revenue increased 8%, and year-over-year operating expenses decreased 5% as Vivos sets the stage for its Sleep Center of Nevada acquisition and continued advancement of its new marketing and distribution model Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of ...

Accelsius continues to build momentum within the large and growing liquid cooling market Innventure reiterates confidence in achieving revenue growth inflection during the second half of 2025 ORLANDO, Fla., May 15, 2025 (GLOBE NEWSWIRE) -- Innventure, Inc. (NASDAQ: INV) (“Innventure”), a technology commercialization platform, today announced financial results for the quarter ended March 31, 2025. “Innventure’s operating companies continued their momentum to start 2025, with both Accelsius and AeroFlexx furt ...

Core Insights - Fortress Biotech, Inc. has initiated the commercial launch of Emrosi™ for treating inflammatory lesions of rosacea in adults, following FDA approval in November 2024 [4] - The company reported a net loss of $(12.7) million, or $(0.48) per share, for Q1 2025, an improvement from a net loss of $(17.9) million, or $(1.04) per share, in Q1 2024 [12][18] - Fortress' subsidiary Checkpoint Therapeutics is set to be acquired by Sun Pharma, with expected upfront cash payment of approximately $28 million and potential future royalties [3][2] Financial Results - Fortress' consolidated cash and cash equivalents increased to $91.3 million as of March 31, 2025, up from $57.3 million at the end of 2024, marking a $34 million increase [12][14] - Consolidated net product revenue for Q1 2025 was $13.1 million, slightly up from $13.0 million in Q1 2024 [9][18] - Research and development expenses for Q1 2025 totaled $3.9 million, a significant decrease from $24.8 million in Q1 2024 [12][18] Regulatory Updates - The FDA accepted the New Drug Application for CUTX-101 for Menkes disease, with a PDUFA goal date of September 30, 2025 [2][8] - UNLOXCYT, an anti-PD-L1 antibody developed by Checkpoint, was approved by the FDA in December 2024 for treating patients with metastatic or locally advanced cutaneous squamous cell carcinoma [8] Commercial Product Updates - Emrosi was launched by Journey Medical Corporation, with initial prescriptions filled at the end of March 2025 [4][18] - Full results from two Phase 3 clinical trials evaluating Emrosi were published, demonstrating its efficacy and safety for treating moderate-to-severe papulopustular rosacea [18] Corporate Highlights - Fortress has a robust pipeline with multiple late-stage programs and newly approved products, positioning the company for continued revenue growth [2] - The acquisition of Checkpoint by Sun Pharma is expected to enhance patient access to Checkpoint's products and create significant monetization opportunities for Fortress [3][2]

Financial Results Announcement - Petco Health and Wellness Company, Inc. will release its financial results for the first quarter of fiscal 2025 after market close on June 5, 2025 [1] - A conference call to discuss the results will be held at 4:30 p.m. Eastern time on the same day [1] Webcast Information - A live webcast of the conference call will be available on the company's Investor Relations page [2] - A replay of the webcast will be accessible approximately two hours after the conference call [2] Company Overview - Petco, founded in 1965, is focused on improving the lives of pets, pet parents, and its partners [3] - The company operates over 1,500 pet care centers across the U.S., Mexico, and Puerto Rico, offering a variety of services including grooming, training, and veterinary care [3] - Petco Love, an independent nonprofit organization, collaborates with local animal welfare groups and has facilitated the adoption of nearly 7 million animals [3]

Core Insights - Century Therapeutics is advancing its pipeline of induced pluripotent stem cell (iPSC)-derived therapies for autoimmune diseases and cancer, with significant progress reported in the first quarter of 2025 [1][2]. Financial Results - As of March 31, 2025, the company reported cash, cash equivalents, and marketable securities totaling $185.8 million, down from $220.1 million at the end of 2024, which is expected to support operations into Q4 2026 [11]. - Collaboration revenue for the first quarter of 2025 was $109.2 million, a substantial increase from $0.9 million in the same period of 2024, attributed to a collaboration agreement with Bristol-Myers Squibb, which was terminated on March 12, 2025 [11]. - Research and Development (R&D) expenses rose to $26.6 million in Q1 2025 from $23.4 million in Q1 2024, primarily due to increased clinical trial costs [11]. - General and Administrative (G&A) expenses decreased slightly to $8.4 million from $8.7 million year-over-year [11]. - The company reported a net income of $76.6 million for Q1 2025, compared to a net loss of $28.1 million in Q1 2024 [11]. Pipeline Developments - The company is on track to initiate Investigational New Drug (IND)-enabling studies for its lead preclinical program, CNTY-308, in mid-2025 [2][11]. - Patient dosing has commenced in the Phase 1 CALiPSO-1 trial for CNTY-101, with plans to expand into additional U.S. and European sites [5][6]. - Presentations at the ASGCT 28th Annual Meeting highlighted advancements in the preclinical pipeline, including improvements in anti-tumor activity of iPSC-derived immunotherapies [4][5]. Strategic Focus - Century Therapeutics is committed to developing off-the-shelf cell therapies to enhance patient access and improve treatment outcomes for autoimmune diseases and cancers [9]. - The company is leveraging its expertise in cellular reprogramming and genetic engineering to create scalable and accessible CAR-T cell therapies [7][11].

Core Insights - Rent the Runway, Inc. is set to release its first quarter 2025 financial results on June 5, 2025, after market close [1] - A conference call and live webcast will be held at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a business update [1] Company Overview - Founded in 2009, Rent the Runway is transforming the trillion-dollar fashion industry with its "Closet in the Cloud" concept [4] - The company's mission is to empower women to feel their best every day through subscription services, rental items, and resale options from hundreds of designer brands [4] - Rent the Runway offers a diverse assortment of millions of items for various occasions, including evening wear, accessories, workwear, and activewear [4] - The company has developed a two-sided discovery engine that connects engaged customers with differentiated brand partners, leveraging its brand, data, logistics, and technology [4] - Under the leadership of CEO and Co-Founder Jennifer Hyman, Rent the Runway has been recognized multiple times on CNBC's "Disruptor 50" and Fast Company's Most Innovative Companies list [4]